Abstract
The main types of gynecologic cancers (GCs) include ovarian, uterine (endometrial cancer and uterine sarcoma), and cervical. In spite of often being grouped together, each GC has distinct risk factors, signs and symptoms, and prognosis. Similar to other malignancies, one of the main clinical challenges in treating GCs is the cancer’s ability to develop resistance. Cancer stem cells (CSCs) have been implicated as the cause for this resistance, and therefore, by targeting them, there is the possibility of tumor regression. Cell-surface markers, such as CD24, CD44, and CD133, are commonly used in the identification of CSCs. In particular, CD133, which is a transmembrane glycoprotein, has been used either alone or in collaboration with other markers in order to identify CSCs from different solid tumors, including GCs. There is mounting evidence that CD133 might be responsible for CSC tumorigenesis, metastasis, and chemoresistance. So, by understanding the molecular biology of CD133, CSCs can be isolated and targeted as part of therapeutic strategies. In this chapter, the clinical relevance of CD133 in GCs is discussed, with a focus on the utility and limitations of using CD133 for CSC identification and therapeutic targeting.
This is a preview of subscription content, log in via an institution to check access.
References
Aghajani M, Mansoori B, Mohammadi A, Asadzadeh Z, Baradaran B (2019) New emerging roles of CD133 in cancer stem cell: signaling pathway and miRNA regulation. J Cell Physiol 234(12):21642–21661. https://doi.org/10.1002/jcp.28824
Akbarzadeh M, Maroufi NF, Tazehkand AP, Akbarzadeh M, Bastani S, Safdari R, Farzane A, Fattahi A, Nejabati HR, Nouri M, Samadi N (2019) Current approaches in identification and isolation of cancer stem cells. J Cell Physiol. https://doi.org/10.1002/jcp.28271
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100:3983–3988. https://doi.org/10.1073/pnas.0530291100
Alibolandi M, Abnous K, Anvari S, Mohammadi M, Ramezani M, Taghdisi SM (2018) CD133-targeted delivery of self-assembled PEGylated carboxymethylcellulose-SN38 nanoparticles to colorectal cancer. Artif Cells Nanomed Biotechnol 46(sup1):1159–1169. https://doi.org/10.1080/21691401.2018.1446969
Alkatout I, Schubert M, Garbrecht N, Weigel MT, Jonat W, Mundhenke C, Günther V (2015) Vulvar cancer: epidemiology, clinical presentation, and management options. Int J Women’s Health 7:305–313. https://doi.org/10.2147/IJWH.S68979
Almanaa TN, Geusz ME, Jamasbi RJ (2013) A new method for identifying stem-like cells in esophageal cancer cell lines. J Cancer 4:536–548. https://doi.org/10.7150/jca.6477
Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I (2005) Endometrial cancer. Lancet 366:491–505. https://doi.org/10.1016/S0140-6736(05)67063-8
Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, Bray F (2020) Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health 8:e191–e203. https://doi.org/10.1016/S2214-109X(19)30482-6
Ayub TH, Keyver-Paik MD, Debald M, Rostamzadeh B, Thiesler T, Schröder L, Barchet W, Abramian A, Kaiser C, Kristiansen G, Kuhn W, Kübler K (2015) Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer. Oncotarget 6:16437–16448. https://doi.org/10.18632/oncotarget.4103
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756–760. https://doi.org/10.1038/nature05236
Barroso JCM, Santos MC (2014) Cancer stem cells in gynecologic cancer. In: Grande E, Antón Aparicio L (eds) Stem cells in cancer: should we believe or not? Springer, Dordrecht, pp 263–290
Barzegar Behrooz A, Syahir A, Ahmad S (2019) CD133: beyond a cancer stem cell biomarker. J Drug Target 27:257–269. https://doi.org/10.1080/1061186X.2018.1479756
Basu AK (2018) DNA damage, mutagenesis and cancer. Int J Mol Sci 19:970. https://doi.org/10.3390/ijms19040970
Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U, Beier CP (2007) CD133(+) and CD133(−) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 67:4010–4015. https://doi.org/10.1158/0008-5472.CAN-06-4180
Bell DW, Ellenson LH (2019) Molecular genetics of endometrial carcinoma. Annu Rev Pathol 14:339–367. https://doi.org/10.1146/annurev-pathol-020117-043609
Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S, Roz E, Caserini R, Lo Vullo S, Camerini T, Mariani L, Delia D, Calabrò E, Pastorino U, Sozzi G (2009) Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A 106:16281–16286. https://doi.org/10.1073/pnas.0905653106
Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann JA, Leitao MM, Powell MA, Poveda A, Beale P, Glasspool RM, Creutzberg CL, Harter P, Kim JW, Reed NS, Ray-Coquard I (2014) Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma. Int J Gynecol Cancer 24:S55–S60. https://doi.org/10.1097/IGC.0000000000000228
Bidlingmaier S, Zhu X, Liu B (2008) The utility and limitations of glycosylated human CD133 epitopes in defning cancer stem cells. J Mol Med (Berl) 86:1025–1032. https://doi.org/10.1007/s00109-008-0357-8
Blackadar CB (2016) Historical review of the causes of cancer. World J Clin Oncol 7:54–86. https://doi.org/10.5306/wjco.v7.i1.54
Bogaerts E, Heindryckx F, Vandewynckel YP, Van Grunsven LA, Van Vlierberghe H (2014) The roles of transforming growth factor-β, Wnt, Notch and hypoxia on liver progenitor cells in primary liver tumours (Review). Int J Oncol 44:1015–1022. https://doi.org/10.3892/ijo.2014.2286
Boivin D, Labbé D, Fontaine N, Lamy S, Beaulieu E, Gingras D, Béliveau R (2009) The stem cell marker CD133 (prominin-1) is phosphorylated on cytoplasmic tyrosine-828 and tyrosine-852 by Src and Fyn tyrosine kinases. Biochemistry 48:3998–4007. https://doi.org/10.1021/bi900159d
Bourseau-Guilmain E, Griveau A, Benoit JP, Garcion E (2011) The importance of the stem cell marker prominin-1/CD133 in the uptake of transferrin and in iron metabolism in human colon cancer Caco-2 cells. PLoS One 6:e25515. https://doi.org/10.1371/journal.pone.0025515
Braaten KP, Laufer MR (2008) Human papillomavirus (HPV), HPV-related disease, and the HPV vaccine. Rev Obstet Gynecol 1:2–10
Brooks RA, Fleming GF, Lastra RR, Lee NK, Moroney JW, Son CH, Tatebe K, Veneris JL (2019) Current recommendations and recent progress in endometrial cancer. CA Cancer J Clin 69:258–279. https://doi.org/10.3322/caac.21561
Bussolati B, Moggio A, Collino F, Aghemo G, D’Armento G, Grange C, Camussi G (2012) Hypoxia modulates the undiferentiated phenotype of human renal inner medullary CD133+ progenitors through Oct4/miR145 balance. Am J Physiol Renal Physiol 302:F116–F128. https://doi.org/10.1152/ajprenal.00184.2011
Cai J, Peng T, Wang J, Zhang J, Hu H, Tang D, Chu C, Yang T, Liu H (2016) Isolation, culture and identification of choriocarcinoma stem-like cells from the human choriocarcinoma cell-line JEG-3. Cell Physiol Biochem 39:1421–1432. https://doi.org/10.1159/000447845
Campisi J, d’Adda di Fagagna F (2007) Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 8:729–740. https://doi.org/10.1038/nrm2233
Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497:67–73. https://doi.org/10.1038/nature12113
Cantrell LA, Blank SV, Duska LR (2015) Uterine carcinosarcoma: a review of the literature. Gynecol Oncol 137:581–588. https://doi.org/10.1016/j.ygyno.2015.03.041
Cehajic-Kapetanovic J, Birtel J, McClements ME, Shanks ME, Clouston P, Downes SM, Charbel Issa P, MacLaren RE (2019) Clinical and molecular characterization of PROM1-related retinal degeneration. JAMA Netw Open 2:e195752. https://doi.org/10.1001/jamanetworkopen.2019.5752
Cherniack AD, Shen H, Walter V, Stewart C, Murray BA, Bowlby R, Hu X, Ling S, Soslow RA, Broaddus RR, Zuna RE, Robertson G, Laird PW, Kucherlapati R, Mills GB, Cancer Genome Atlas Research Network, Weinstein JN, Zhang J, Akbani R, Levine DA (2017) Integrated molecular characterization of uterine Carcinosarcoma. Cancer Cell 31:411–423. https://doi.org/10.1016/j.ccell.2017.02.010
Choi CH, Chung JY, Kang JH, Paik ES, Lee YY, Park W, Byeon SJ, Chung EJ, Kim BG, Hewitt SM, Bae DS (2020) Chemoradiotherapy response prediction model by proteomic expressional profiling in patients with locally advanced cervical cancer. Gynecol Oncol 157:437–443. https://doi.org/10.1016/j.ygyno.2020.02.017
Choi YJ, Ingram PN, Yang K, Coffman L, Iyengar M, Bai S, Thomas DG, Yoon E, Buckanovich RJ (2015) Identifying an ovarian cancer cell hierarchy regulated by bone morphogenetic protein 2. Proc Natl Acad Sci U S A 112:E6882–E6888. https://doi.org/10.1073/pnas.1507899112
Choijamts B, Jimi S, Kondo T, Naganuma Y, Matsumoto T, Kuroki M, Iwasaki H, Emoto M (2011) CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Müllerian tumor). Stem Cells 29:1485–1495. https://doi.org/10.1002/stem.711
Chuthapisith S, Eremin J, El-Sheemey M, Eremin O (2010) Breast cancer chemoresistance: emerging importance of cancer stem cells. Surg Oncol 19:27–322. https://doi.org/10.1016/j.suronc.2009.01.004
Cioffi M, D’Alterio C, Camerlingo R, Tirino V, Consales C, Riccio A, Ieranò C, Cecere SC, Losito NS, Greggi S, Pignata S, Pirozzi G, Scala S (2015) Identification of a distinct population of CD133(+)CXCR4(+) cancer stem cells in ovarian cancer. Sci Rep 5:10357. https://doi.org/10.1038/srep10357
Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O’Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS (2017) Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 18:779–791. https://doi.org/10.1016/S1470-2045(17)30279-6
Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65:10946–10951. https://doi.org/10.1158/0008-5472.CAN-05-2018
Colombo N, Carinelli S, Marini C, Rollo D, Sessa C (2012) Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23:vii27–vii32. https://doi.org/10.1093/annonc/mds268
Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, Ledermann J, Bosse T, Chargari C, Fagotti A, Fotopoulou C, Martin AG, Lax S, Lorusso D, Marth C, Morice P, Nout RA, O’Donnell D, Querleu D, Raspollini MR, Sehouli J, Sturdza A, Taylor A, Westermann A, Wimberger P, Colombo N, Planchamp F, Creutzberg CL (2021) ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Radiother Oncol 154:327–353. https://doi.org/10.1016/j.radonc.2020.11.018
Coppé JP, Patil CK, Rodier F, Sun Y, Muñoz DP, Goldstein J, Nelson PS, Desprez PY, Campisi J (2008) Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 6:2853–2868. https://doi.org/10.1371/journal.pbio.0060301
Corbeil D, Marzesco AM, Wilsch-Bräuninger M, Huttner WB (2010) The intriguing links between prominin-1 (CD133), cholesterol-based membrane microdomains, remodeling of apical plasma membrane protrusions, extracellular membrane particles, and (neuro)epithelial cell differentiation. FEBS Lett 584:1659–1664. https://doi.org/10.1016/j.febslet.2010.01.050
Corbeil D, Röper K, Fargeas CA, Joester A, Huttner WB (2001) Prominin: a story of cholesterol, plasma membrane protrusions and human pathology. Traffic 2:82–91. https://doi.org/10.1034/j.1600-0854.2001.020202.x
Corrò C, Moch H (2018) Biomarker discovery for renal cancer stem cells. J Pathol Clin Res 4(1):3–18. https://doi.org/10.1002/cjp2.91
Cortez AJ, Tudrej P, Kujawa KA, Lisowska KM (2018) Advances in ovarian cancer therapy. Cancer Chemother Pharmacol 81:17–38. https://doi.org/10.1007/s00280-017-3501-8
Deleyrolle LP, Harding A, Cato K, Siebzehnrubl FA, Rahman M, Azari H, Olson S, Gabrielli B, Osborne G, Vescovi A, Reynolds BA (2011) Evidence for label-retaining tumour-initiating cells in human glioblastoma. Brain 134:1331–1343. https://doi.org/10.1093/brain/awr081
Deleyrolle LP, Rohaus MR, Fortin JM, Reynolds BA, Azari H (2012) Identification and isolation of slow-dividing cells in human glioblastoma using carboxy fluorescein succinimidyl ester (CFSE). J Vis Exp 62:3918. https://doi.org/10.3791/3918
Desiderio V, Papagerakis P, Tirino V, Zheng L, Matossian M, Prince ME, Paino F, Mele L, Papaccio F, Montella R, Papaccio G, Papagerakis S (2015) Increased fucosylation has a pivotal role in invasive and metastatic properties of head and neck cancer stem cells. Oncotarget 6:71–84. https://doi.org/10.18632/oncotarget.2698
Di Fiore R, Suleiman S, Ellul B, O’Toole SA, Savona-Ventura C, Felix A, Napolioni V, Conlon NT, Kahramanoglu I, Azzopardi MJ, Dalmas M, Calleja N, Brincat MR, Muscat-Baron Y, Sabol M, Dimitrievska V, Yordanov A, Vasileva-Slaveva M, von Brockdorff K, Micallef RA, Kubelac P, Achimaș-Cadariu P, Vlad C, Tzortzatou O, Poka R, Giordano A, Felice A, Reed N, Herrington CS, Faraggi D, Calleja-Agius J (2021) GYNOCARE update: modern strategies to improve diagnosis and treatment of rare gynecologic tumors—current challenges and future directions. Cancers (Basel) 13:493. https://doi.org/10.3390/cancers13030493
Ding DC, Liu HW, Chang YH, Chu TY (2017) Expression of CD133 in endometrial cancer cells and its implications. J Cancer 8:2142–2153. https://doi.org/10.7150/jca.18869
Duan JJ, Qiu W, Xu SL, Wang B, Ye XZ, Ping YF, Zhang X, Bian XW, Yu SC (2013) Strategies for isolating and enriching cancer stem cells: well begun is half done. Stem Cells Dev 22:2221–2239. https://doi.org/10.1089/scd.2012.0613
Dubeau L, Drapkin R (2013) Coming into focus: the nonovarian origins of ovarian cancer. Ann Oncol 24(Suppl 8):viii28–viii35. https://doi.org/10.1093/annonc/mdt308
Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, García-Echeverría C, Schultz PG, Reddy VA (2009) The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci U S A 106:268–273. https://doi.org/10.1073/pnas.0810956106
Dwivedi S, Rao G, Dey A, Mukherjee P, Wren JD, Bhattacharya R (2021) Small non-coding-RNA in gynecological malignancies. Cancers 13:1085. https://doi.org/10.3390/cancers13051085
Dyall S, Gayther SA, Dafou D (2010) Cancer stem cells and epithelial ovarian cancer. J Oncol 2010:105269. https://doi.org/10.1155/2010/105269
Elbasateeny SS, Salem AA, Abdelsalam WA, Salem RA (2016) Immunohistochemical expression of cancer stem cell related markers CD44 and CD133 in endometrial cancer. Pathol Res Pr 212:10–16. https://doi.org/10.1016/j.prp.2015.10.008
Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C, De Maria R (2008) Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15:504–514. https://doi.org/10.1038/sj.cdd.4402283
Ewald JA, Desotelle JA, Wilding G, Jarrard DF (2010) Therapy-induced senescence in cancer. J Natl Cancer Inst 102:1536–1546. https://doi.org/10.1093/jnci/djq364
Evrard C, Alexandre J (2021) Predictive and prognostic value of microsatellite instability in gynecologic cancer (endometrial and ovarian). Cancers (Basel) 13(10):2434. https://doi.org/10.3390/cancers13102434
Fadare O, Zheng W (2009) Insights into endometrial serous carcinogenesis and progression. Int J Clin Exp Pathol 2:411–432
Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE, Herlyn M (2005) A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65:9328–9337. https://doi.org/10.1158/0008-5472.CAN-05-1343
Fargeas CA, Joester A, Missol-Kolka E, Hellwig A, Huttner WB, Corbeil D (2004) Identifcation of novel Prominin-1/CD133 splice variants with alternative C-termini and their expression in epididymis and testis. J Cell Sci 117:4301–4311. https://doi.org/10.1242/jcs.01315
Fargeas CA, Karbanová J, Jászai J, Corbeil D (2011) CD133 and membrane microdomains: old facets for future hypotheses. World J Gastroenterol 17:4149–4152. https://doi.org/10.3748/wjg.v17.i36.4149
Farkas LM, Huttner WB (2008) The cell biology of neural stem and progenitor cells and its significance for their proliferation versus differentiation during mammalian brain development. Curr Opin Cell Biol 20:707–715. https://doi.org/10.1016/j.ceb.2008.09.008
Farnie G, Clarke RB, Spence K, Pinnock N, Brennan K, Anderson NG, Bundred NJ (2007) Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. J Natl Cancer Inst 99:616–627. https://doi.org/10.1093/jnci/djk133
Ferrandina G, Bonanno G, Pierelli L, Perillo A, Procoli A, Mariotti A, Corallo M, Martinelli E, Rutella S, Paglia A, Zannoni G, Mancuso S, Scambia G (2008) Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer 18:506–514. https://doi.org/10.1111/j.1525-1438.2007.01056.x
Fields EC, Hazell S, Morcos M, Schmidt EJ, Chargari C, Viswanathan AN (2020) Image-guided gynecologic brachytherapy for cervical cancer. Semin Radiat Oncol 30:16–28. https://doi.org/10.1016/j.semradonc.2019.08.010
Friel AM, Zhang L, Curley MD, Therrien VA, Sergent PA, Belden SE, Borger DR, Mohapatra G, Zukerberg LR, Foster R, Rueda BR (2010) Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells. Reprod Biol Endocrinol 8:147. https://doi.org/10.1186/1477-7827-8-147
Fujiwara T, Katsuda T, Hagiwara K, Kosaka N, Yoshioka Y, Takahashi RU, Takeshita F, Kubota D, Kondo T, Ichikawa H, Yoshida A, Kobayashi E, Kawai A, Ozaki T, Ochiya T (2014) Clinical relevance and therapeutic significance of microRNA-133a expression profiles and functions in malignant osteosarcoma-initiating cells. Stem Cells 32:959–973. https://doi.org/10.1002/stem.1618
García-Rocha R, Monroy-García A, Hernández-Montes J, Weiss-Steider B, Gutiérrez-Serrano V, Del Carmen F-CM, Ávila-Ibarra LR, Don-López CA, Torres-Pineda DB, de Lourdes M-GM (2019) Cervical cancer cells produce TGF-β1 through the CD73-adenosine pathway and maintain CD73 expression through the autocrine activity of TGF-β1. Cytokine 118:71–79. https://doi.org/10.1016/j.cyto.2018.09.018
Geddert H, Braun A, Kayser C, Dimmler A, Faller G, Agaimy A, Haller F, Moskalev EA (2017) Epigenetic regulation of CD133 in gastrointestinal stromal tumors. Am J Clin Pathol 147:515–524. https://doi.org/10.1093/ajcp/aqx028
Giannone G, Attademo L, Scotto G, Genta S, Ghisoni E, Tuninetti V, Aglietta M, Pignata S, Valabrega G (2019) Endometrial cancer stem cells: role, characterization and therapeutic implications. Cancers (Basel) 11:1820. https://doi.org/10.3390/cancers11111820
Gilani MM, Fariba B, Behtash N, Ghaemmaghami F, Moosavi AS, Rezayof E (2013) The WHO score predicts treatment outcome in low risk gestational trophoblastic neoplasia patients treated with weekly intramuscular methotrexate. J Cancer Res Ther 9:38–43. https://doi.org/10.4103/0973-1482.110357
Giraud J, Failla LM, Pascussi JM, Lagerqvist EL, Ollier J, Finetti P, Bertucci F, Ya C, Gasmi I, Bourgaux JF, Prudhomme M, Mazard T, Ait-Arsa I, Houhou L, Birnbaum D, Pélegrin A, Vincent C, Ryall JG, Joubert D, Pannequin J, Hollande F (2016) Autocrine secretion of progastrin promotes the survival and self-renewal of colon cancer stem-like cells. Cancer Res 76:3618–3628. https://doi.org/10.1158/0008-5472.CAN-15-1497
Glumac PM, LeBeau AM (2018) The role of CD133 in cancer: a concise review. Clin Transl Med 7:18. https://doi.org/10.1186/s40169-018-0198-1
Gopisetty G, Xu J, Sampath D, Colman H, Puduvalli VK (2013) Epigenetic regulation of CD133/PROM1 expression in glioma stem cells by Sp1/myc and promoter methylation. Oncogene 32:3119–3129. https://doi.org/10.1038/onc.2012.331
Gorai I, Yanagibashi T, Taki A, Udagawa K, Miyagi E, Nakazawa T, Hirahara F, Nagashima Y, Minaguchi H (1997) Uterine carcinosarcoma is derived from a single stem cell: an in vitro study. Int J Cancer 72:821–827. https://doi.org/10.1002/(sici)1097-0215(19970904)72:5<821::aid-ijc19>3.0.co;2-b
Greve B, Kelsch R, Spaniol K, Eich HT, Götte M (2012) Flow cytometry in cancer stem cell analysis and separation. Cytometry A 81:284–293. https://doi.org/10.1002/cyto.a.22022
Griguer CE, Oliva CR, Gobin E, Marcorelles P, Benos DJ, Lancaster JR Jr, Gillespie GY (2008) CD133 is a marker of bioenergetic stress in human glioma. PLoS One 3:e3655. https://doi.org/10.1371/journal.pone.0003655
Grosse-Gehling P, Fargeas CA, Dittfeld C, Garbe Y, Alison MR, Corbeil D, Kunz-Schughart LA (2013) CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges. J Pathol 229(3):355–378. https://doi.org/10.1002/path.4086
Gujral TS, Chan M, Peshkin L, Sorger PK, Kirschner MW, MacBeath G (2014) A noncanonical Frizzled2 pathway regulates epithelial-mesenchymal transition and metastasis. Cell 159:844–856. https://doi.org/10.1016/j.cell.2014.10.032
Han Z, Chen Z, Zheng R, Cheng Z, Gong X, Wang D (2015) Clinicopathological significance of CD133 and CD44 expression in infiltrating ductal carcinoma and their relationship to angiogenesis. World J Surg Oncol 13:56. https://doi.org/10.1186/s12957-015-0486-9
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. https://doi.org/10.1016/j.cell.2011.02.013
Hapsari K, Bhugwandass C, van Rijn GWJ, van Der Wurff AAM, van’t Veer M, Boll D, Vos MC, Pijlman B, Kok A, Piek JMJ (2020) Treatment and outcome of patients with uterine Carcinosarcoma in a comprehensive cancer network. Indian J Gynecol Oncol 18:17. https://doi.org/10.1007/s40944-019-0362-6
Herfs M, Yamamoto Y, Laury A, Wang X, Nucci MR, McLaughlin-Drubin ME, Münger K, Feldman S, McKeon FD, Xian W, Crum CP (2012) A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc Natl Acad Sci U S A 109:10516–10521. https://doi.org/10.1073/pnas.1202684109
Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1:313–323. https://doi.org/10.1016/j.stem.2007.06.002
Hermansen SK, Christensen KG, Jensen SS, Kristensen BW (2011) Inconsistent immunohistochemical expression patterns of four different CD133 antibody clones in glioblastoma. J Histochem Cytochem 59(4):391–407. https://doi.org/10.1369/0022155411400867
Horst D, Scheel SK, Liebmann S, Neumann J, Maatz S, Kirchner T, Jung A (2009) The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. J Pathol 219:427–434. https://doi.org/10.1002/path.2597
Hsu HS, Huang PI, Chang YL, Tzao C, Chen YW, Shih HC, Hung SC, Chen YC, Tseng LM, Chiou SH (2011) Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells. Cancer 117:2970–2985. https://doi.org/10.1002/cncr.25869
Husain RS, Ramakrishnan V (2015) Global variation of human papillomavirus genotypes and selected genes involved in cervical malignancies. Ann Glob Health 81:675–683. https://doi.org/10.1016/j.aogh.2015.08.026
Ieta K, Tanaka F, Haraguchi N, Kita Y, Sakashita H, Mimori K, Matsumoto T, Inoue H, Kuwano H, Mori M (2008) Biological and genetic characteristics of tumor-initiating cells in colon cancer. Ann Surg Oncol 15:638–648. https://doi.org/10.1245/s10434-007-9605-3
Iida H, Suzuki M, Goitsuka R, Ueno H (2012) Hypoxia induces CD133 expression in human lung cancer cells by up-regulation of OCT3/4 and SOX2. Int J Oncol 40:71–79. https://doi.org/10.3892/ijo.2011.1207
Immervoll H, Hoem D, Sakariassen PØ, Steffensen OJ, Molven A (2008) Expression of the “stem cell marker” CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer 8:48. https://doi.org/10.1186/1471-2407-8-48
Ishigami S, Ueno S, Arigami T, Uchikado Y, Setoyama T, Arima H, Kita Y, Kurahara H, Okumura H, Matsumoto M, Kijima Y, Natsugoe S (2010) Prognostic impact of CD133 expression in gastric carcinoma. Anticancer Res 30:2453–2457
Ishiguro T, Sato A, Ohata H, Ikarashi Y, Takahashi RU, Ochiya T, Yoshida M, Tsuda H, Onda T, Kato T, Kasamatsu T, Enomoto T, Tanaka K, Nakagama H, Okamoto K (2016) Establishment and characterization of an in vitro model of ovarian cancer stem-like cells with an enhanced proliferative capacity. Cancer Res 76:150–160. https://doi.org/10.1158/0008-5472.CAN-15-0361
Jain RK (2014) Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 26(5):605–622. https://doi.org/10.1016/j.ccell.2014.10.006
Javed S, Sharma BK, Sood S, Sharma S, Bagga R, Bhattacharyya S, Rayat CS, Dhaliwal L, Srinivasan R (2018) Significance of CD133 positive cells in four novel HPV-16 positive cervical cancer-derived cell lines and biopsies of invasive cervical cancer. BMC Cancer 18:357. https://doi.org/10.1186/s12885-018-4237-5
Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L, Wang H, Liu Z, Su Y, Stass SA, Katz RL (2009) Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 7:330–338. https://doi.org/10.1158/1541-7786.MCR-08-0393
Joseph C, Arshad M, Kurozomi S, Althobiti M, Miligy IM, Al-Izzi S, Toss MS, Goh FQ, Johnston SJ, Martin SG, Ellis IO, Mongan NP, Green AR, Rakha EA (2019) Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer. Breast Cancer Res Treat 174:387–399. https://doi.org/10.1007/s10549-018-05085-9
Kakarala M, Brenner DE, Korkaya H, Cheng C, Tazi K, Ginestier C, Liu S, Dontu G, Wicha MS (2010) Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res Treat 122:777–785. https://doi.org/10.1007/s10549-009-0612-x
Kemper K, Sprick MR, de Bree M, Scopelliti A, Vermeulen L, Hoek M, Zeilstra J, Pals ST, Mehmet H, Stassi G, Medema JP (2010) The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res 70:719–729. https://doi.org/10.1158/0008-5472.CAN-09-1820
Keyvani V, Farshchian M, Esmaeili SA, Yari H, Moghbeli M, Nezhad SK, Abbaszadegan MR (2019) Ovarian cancer stem cells and targeted therapy. J Ovarian Res 12:120. https://doi.org/10.1186/s13048-019-0588-z
Khan MI, Czarnecka AM, Helbrecht I, Bartnik E, Lian F, Szczylik C (2015) Current approaches in identification and isolation of human renal cell carcinoma cancer stem cells. Stem Cell Res Ther 6:178. https://doi.org/10.1186/s13287-015-0177-z
Kim YJ, Siegler EL, Siriwon N, Wang P (2016) Therapeutic strategies for targeting cancer stem cells. J Cancer Metastasis Treat 2:233–242. https://doi.org/10.20517/2394-4722.2016.26
Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, Chon HS, Chu C, Clark R, Cohn D, Crispens MA, Damast S, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, Han E, Huh WK, Lurain JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Ueda S, Wyse E, Yashar CM, McMillian NR, Scavone JL (2019) Cervical cancer, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 17:64–84. https://doi.org/10.6004/jnccn.2019.0001
Koshiyama M, Matsumura N, Konishi I (2014) Recent concepts of ovarian carcinogenesis: type I and type II. Biomed Res Int 2014:934261. https://doi.org/10.1155/2014/934261
Kroon P, Berry PA, Stower MJ, Rodrigues G, Mann VM, Simms M, Bhasin D, Chettiar S, Li C, Li PK, Maitland NJ, Collins AT (2013) JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells. Cancer Res 73:5288–5298. https://doi.org/10.1158/0008-5472.CAN-13-0874
Kryczek I, Liu S, Roh M, Vatan L, Szeliga W, Wei S, Banerjee M, Mao Y, Kotarski J, Wicha MS, Liu R, Zou W (2012) Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int J Cancer 130:29–39. https://doi.org/10.1002/ijc.25967
Kumazawa S, Kajiyama H, Umezu T, Mizuno M, Suzuki S, Yamamoto E, Mitsui H, Sekiya R, Shibata K, Kikkawa F (2014) Possible association between stem-like hallmark and radioresistance in human cervical carcinoma cells. J Obstet Gynaecol Res 40:1389–1398. https://doi.org/10.1111/jog.12357
Kurman RJ, Shih IM (2008) Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 27:151–160. https://doi.org/10.1097/PGP.0b013e318161e4f5
Kurman RJ, Shih IM (2016) The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol 186:733–747. https://doi.org/10.1016/j.ajpath.2015.11.011
Kusumbe AP, Mali AM, Bapat SA (2009) CD133-expressing stem cells associated with ovarian metastases establish an endothelial hierarchy and contribute to tumor vasculature. Stem Cells 27:498–508. https://doi.org/10.1634/stemcells.2008-0868
Lax SF (2004) Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 444:213–223. https://doi.org/10.1007/s00428-003-0947-3
Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L (2000) The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 88:814–824
Lee SWL, Paoletti C, Campisi M, Osaki T, Adriani G, Kamm RD, Mattu C, Chiono V (2019) MicroRNA delivery through nanoparticles. J Control Release 313:80–95. https://doi.org/10.1016/j.jconrel.2019.10.007
Li B, McCrudden CM, Yuen HF, Xi X, Lyu P, Chan KW, Zhang SD, Kwok HF (2017a) CD133 in brain tumor: the prognostic factor. Oncotarget 8:11144–11159. https://doi.org/10.18632/oncotarget.14406
Li H, Wu X, Cheng X (2016) Advances in diagnosis and treatment of metastatic cervical cancer. J Gynecol Oncol 27:e43. https://doi.org/10.3802/jgo.2016.27.e43
Li L, Neaves WB (2006) Normal stem cells and cancer stem cells: the niche matters. Cancer Res 66:4553–4557. https://doi.org/10.1158/0008-5472.CAN-05-3986
Li W, Ma H, Zhang J, Zhu L, Wang C, Yang Y (2017b) Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis. Sci Rep 7:13856. https://doi.org/10.1038/s41598-017-14364-2
Li Y, Jiang N, Ruan DY (2015) Stem cell surface markers CD133 expression in hepatocellular carcinoma and as single prognostic factor for liver transplantation. J Clin Oncol 33(15_suppl):e15166–e15166
Li Z (2013) CD133: a stem cell biomarker and beyond. Exp Hematol Oncol 2:17. https://doi.org/10.1186/2162-3619-2-17
Liu C, Li Y, Xing Y, Cao B, Yang F, Yang T, Ai Z, Wei Y, Jiang J (2016) The interaction between cancer stem cell marker CD133 and Src protein promotes focal adhesion kinase (FAK) phosphorylation and cell migration. J Biol Chem 291:15540–15550. https://doi.org/10.1074/jbc.M115.712976
Liu WH, Wang X, You N, Tao KS, Wang T, Tang LJ, Dou KF (2012) Efficient enrichment of hepatic cancer stem-like cells from a primary rat HCC model via a density gradient centrifugation-centered method. PLoS One 7:e35720. https://doi.org/10.1371/journal.pone.0035720
Liu XF, Yang WT, Xu R, Liu JT, Zheng PS (2014) Cervical cancer cells with positive Sox2 expression exhibit the properties of cancer stem cells. PLoS One 9:e87092. https://doi.org/10.1371/journal.pone.0087092
Liu ZC, Liu WD, Liu YH, Ye XH, Chen SD (2015) Multiple sexual partners as a potential independent risk factor for cervical cancer: a meta-analysis of epidemiological studies. Asian Pac J Cancer Prev 16:3893–3900. https://doi.org/10.7314/apjcp.2015.16.9.3893
Long HJ 3rd, Bundy BN, Grendys EC Jr, Benda JA, DS MM, Sorosky J, Miller DS, Eaton LA, Fiorica JV, Gynecologic Oncology Group Study (2005) Randomized phase III trial of cisplatin with or without topotecan in carci-noma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 23:4626–4633. https://doi.org/10.1200/JCO.2005.10.021
López de Andrés J, Griñán-Lisón C, Jiménez G, Marchal JA (2020) Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment. J Hematol Oncol 13:136. https://doi.org/10.1186/s13045-020-00966-3
López J, Poitevin A, Mendoza-Martínez V, Pérez-Plasencia C, García-Carrancá A (2012) Cancer-initiating cells derived from established cervical cell lines exhibit stem-cell markers and increased radioresistance. BMC Cancer 12:48. https://doi.org/10.1186/1471-2407-12-48
López-Guerrero JA, Romero I, Poveda A (2015) Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer. Chin J Cancer 34:41–49. https://doi.org/10.5732/cjc.014.10278
López-Reig R, Fernández-Serra A, Romero I, Zorrero C, Illueca C, García-Casado Z, Poveda A, López-Guerrero JA (2019) Prognostic classification of endometrial cancer using a molecular approach based on a twelve-gene NGS panel. Sci Rep 9:18093. https://doi.org/10.1038/s41598-019-54624-x
Louie KS, de Sanjose S, Diaz M, Castellsagué X, Herrero R, Meijer CJ, Shah K, Franceschi S, Muñoz N, Bosch FX, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group (2009) Early age at first sexual intercourse and early pregnancy are risk factors for cervical cancer in developing countries. Br J Cancer 100:1191–1197. https://doi.org/10.1038/sj.bjc.6604974
Lu KH, Broaddus RR (2020) Endometrial cancer. N Engl J Med 383:2053–2064. https://doi.org/10.1056/NEJMra1514010
Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, Zheng BJ, Guan XY (2007) Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132:2542–2556. https://doi.org/10.1053/j.gastro.2007.04.025
Ma S, Chan KW, Lee TK, Tang KH, Wo JY, Zheng BJ, Guan XY (2008) Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol Cancer Res 6:1146–1153. https://doi.org/10.1158/1541-7786.MCR-08-0035
Maeda S, Shinchi H, Kurahara H, Mataki Y, Maemura K, Sato M, Natsugoe S, Aikou T, Takao S (2008) CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer 98:1389–1397. https://doi.org/10.1038/sj.bjc.6604307
Maeda K, Ding Q, Yoshimitsu M, Kuwahata T, Miyazaki Y, Tsukasa K, Hayashi T, Shinchi H, Natsugoe S, Takao S (2016) CD133 modulate HIF-1α expression under hypoxia in EMT phenotype pancreatic cancer stem-like cells. Int J Mol Sci 17(7):1025. https://doi.org/10.3390/ijms17071025. PMID: 27367674; PMCID: PMC4964401
Magee JA, Piskounova E, Morrison SJ (2012) Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 21:283–296. https://doi.org/10.1016/j.ccr.2012.03.003
Mahdy H, Casey MJ, Crotzer D Endometrial cancer. (Updated 2021 August 25) In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 January. Available from: https://www.ncbi.nlm.nih.gov/books/NBK525981/
Maheshwari A, Kumar N, Mahantshetty U (2016) Gynecological cancers: a summary of published Indian data. S Asian J Cancer 5:112–120. https://doi.org/10.4103/2278-330X.187575
Mak AB, Blakely KM, Williams RA, Penttilä PA, Shukalyuk AI, Osman KT, Kasimer D, Ketela T, Moffat J (2011) CD133 protein N-glycosylation processing contributes to cell surface recognition of the primitive cell marker AC133 epitope. J Biol Chem 286:41046–41056. https://doi.org/10.1074/jbc.M111.261545
Mak AB, Pehar M, Nixon AM, Williams RA, Uetrecht AC, Puglielli L, Moffat J (2014) Post-translational regulation of CD133 by ATase1/ATase2-mediated lysine acetylation. J Mol Biol 426:2175–2182. https://doi.org/10.1016/j.jmb.2014.02.012
Malpica A, Euscher ED, Hecht JL, Ali-Fehmi R, Quick CM, Singh N, Horn LC, Alvarado-Cabrero I, Matias-Guiu X, Hirschowitz L, Duggan M, Ordi J, Parkash V, Mikami Y, Ruhul Quddus M, Zaino R, Staebler A, Zaloudek C, McCluggage WG, Oliva E (2019) Endometrial carcinoma, grossing and processing issues: recommendations of the International Society of Gynecologic Pathologists. Int J Gynecol Pathol 38(Suppl 1):S9–S24. https://doi.org/10.1097/PGP.0000000000000552
Mancebo G, Sole-Sedeno JM, Pino O, Miralpeix E, Mojal S, Garrigos L, Lloveras B, Navarro P, Gibert J, Lorenzo M, Aran I, Carreras R, Alameda F (2017) Prognostic impact of CD133 expression in endometrial cancer patients. Sci Rep 7:7687. https://doi.org/10.1038/s41598-017-08048-0
Marcato P, Dean CA, Pan D, Araslanova R, Gillis M, Joshi M, Helyer L, Pan L, Leidal A, Gujar S, Giacomantonio CA, Lee PW (2011) Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells 29(1):32–45. https://doi.org/10.1002/stem.563
Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY (2016) Ovarian cancer. Nat Rev Dis Primers 2:16061. https://doi.org/10.1038/nrdp.2016.61
Mauri FA, Pinato DJ, Trivedi P, Sharma R, Shiner RJ (2012) Isogeneic comparison of primary and metastatic lung cancer identifies CX3CR1 as a molecular determinant of site-specific metastatic diffusion. Oncol Rep 28:647–653. https://doi.org/10.3892/or.2012.1818
McLachlan J, Boussios S, Okines A, Glaessgen D, Bodlar S, Kalaitzaki R, Taylor A, Lalondrelle S, Gore M, Kaye S, Banerjee S (2017) The impact of systemic therapy beyond first-line treatment for advanced cervical cancer. Clin Oncol (R Coll Radiol) 29:153–160. https://doi.org/10.1016/j.clon.2016.10.002
Mehrazma M, Madjd Z, Kalantari E, Panahi M, Hendi A, Shariftabrizi A (2013) Expression of stem cell markers, CD133 and CD44, in pediatric solid tumors: a study using tissue microarray. Fetal Pediatr Pathol 32:192–204. https://doi.org/10.3109/15513815.2012.701266
Mendoza-Almanza G, Ortíz-Sánchez E, Rocha-Zavaleta L, Rivas-Santiago C, Esparza-Ibarra E, Olmos J (2019) Cervical cancer stem cells and other leading factors associated with cervical cancer development. Oncol Lett 18:3423–3432. https://doi.org/10.3892/ol.2019.10718
Merchant AA, Matsui W (2010) Targeting Hedgehog–a cancer stem cell pathway. Clin Cancer Res 16:3130–3140. https://doi.org/10.1158/1078-0432.CCR-09-2846
Meyer MJ, Fleming JM, Lin AF, Hussnain SA, Ginsburg E, Vonderhaar BK (2010) CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer. Cancer Res 70:4624–4633. https://doi.org/10.1158/0008-5472.CAN-09-3619
Min KJ, So KA, Ouh YT, Hong JH, Lee JK (2012) The effects of DNA methylation and epigenetic factors on the expression of CD133 in ovarian cancers. J Ovarian Res 5:28. https://doi.org/10.1186/1757-2215-5-28
Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, Bray RA, Waller EK, Buck DW (1997) A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 90:5013–5021
Moghbeli M, Moghbeli F, Forghanifard MM, Abbaszadegan MR (2014) Cancer stem cell detection and isolation. Med Oncol 31:69. https://doi.org/10.1007/s12032-014-0069-6
Moltzahn F, Thalmann GN (2013) Cancer stem cells in prostate cancer. Transl Androl Urol 2:242–253. https://doi.org/10.3978/j.issn.2223-4683.2013.09.06
Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, Benda J, Cella D (2009) Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a gynecologic oncology group study. J Clin Oncol 27:4649–4655. https://doi.org/10.1200/JCO.2009.21.8909
Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, Cavazzin C, Gritti A, Piccinini A, Porro D, Santinami M, Invernici G, Parati E, Alessandri G, La Porta CA (2007) Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 43:935–946. https://doi.org/10.1016/j.ejca.2007.01.017
Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, Miller DS, Olt G, King S, Boggess JF, Rocereto TF (2004) Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 22:3113–3119. https://doi.org/10.1200/JCO.2004.04.170
Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E (2016) Endometrial cancer. Lancet 387:1094–1108. https://doi.org/10.1016/S0140-6736(15)00130-0
Nadal R, Ortega FG, Salido M, Lorente JA, Rodríguez-Rivera M, Delgado-Rodríguez M, Macià M, Fernández A, Corominas JM, García-Puche JL, Sánchez-Rovira P, Solé F, Serrano MJ (2013) CD133 expression in circulating tumor cells from breast cancer patients: potential role in resistance to chemotherapy. Int J Cancer 133:2398–2407. https://doi.org/10.1002/ijc.28263
Nakamura M, Kyo S, Zhang B, Zhang X, Mizumoto Y, Takakura M, Maida Y, Mori N, Hashimoto M, Ohno S, Inoue M (2010) Prognostic impact of CD133 expression as a tumor-initiating cell marker in endometrial cancer. Hum Pathol 41:1516–1529. https://doi.org/10.1016/j.humpath.2010.05.006
Napoletano C, Bellati F, Ruscito I, Pernice M, Zizzari IG, Caponnetto S, Tomao F, Frigerio L, Liberati M, Rughetti A, Caserta D, Panici PB, Nuti M (2016) Immunological and clinical impact of cancer stem cells in vulvar cancer: role of CD133/CD24/ABCG2-expressing cells. Anticancer Res 36:5109–5116. https://doi.org/10.21873/anticanres.11080
Nassar D, Blanpain C (2016) Cancer stem cells: basic concepts and therapeutic implications. Annu Rev Pathol Mech Dis 11:47–76. https://doi.org/10.1146/annurev-pathol-012615-044438
Neuzil J, Stantic M, Zobalova R, Chladova J, Wang X, Prochazka L, Dong L, Andera L, Ralph SJ (2007) Tumour-initiating cells vs. cancer ‘stem’ cells and CD133: what’s in the name? Biochem Biophys Res Commun 355:855–859. https://doi.org/10.1016/j.bbrc.2007.01.159
Ni C, Huang J (2013) Dynamic regulation of cancer stem cells and clinical challenges. Clin Transl Oncol 15:253–258. https://doi.org/10.1007/s12094-012-0927-7
Nomura A, Banerjee S, Chugh R, Dudeja V, Yamamoto M, Vickers SM, Saluja AK (2015) CD133 initiates tumors, induces epithelial-mesenchymal transition and increases metastasis in pancreatic cancer. Oncotarget 6:8313–8322. https://doi.org/10.18632/oncotarget.3228
O’Brien CA, Pollett A, Gallinger S, Dick JE (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445:106–110. https://doi.org/10.1038/nature05372
Okuda T, Sekizawa A, Purwosunu Y, Nagatsuka M, Morioka M, Hayashi M, Okai T (2010) Genetics of endometrial cancers. Obstet Gynecol Int 2010:1–8. https://doi.org/10.1155/2010/984013
Olempska M, Eisenach PA, Ammerpohl O, Ungefroren H, Fandrich F, Kalthoff H (2007) Detection of tumor stem cell markers in pancreatic carcinoma cell lines. Hepatobiliary Pancreat Dis Int 6:92–97
Organista-Nava J, Gómez-Gómez Y, Garibay-Cerdenares OL, Leyva-Vázquez MA, Illades-Aguiar B (2019) Cervical cancer stem cell-associated genes: prognostic implications in cervical cancer. Oncol Lett 18:7–14. https://doi.org/10.3892/ol.2019.10307
Park JY, Hong D (2019) Association between morphological patterns of myometrial invasion and cancer stem cell markers in endometrial Endometrioid carcinoma. Pathol Oncol Res 25:123–130. https://doi.org/10.1007/s12253-017-0320-5
Passarello K, Kurian S, Villanueva V (2019) Endometrial cancer: An overview of pathophysiology, management, and care. Semin Oncol Nurs 35:157–165. https://doi.org/10.1016/j.soncn.2019.02.002
Pastrana E, Silva-Vargas V, Doetsch F (2011) Eyes wide open: a critical review of sphere-formation as an assay for stem cells. Cell Stem Cell 8:486–498. https://doi.org/10.1016/j.stem.2011.04.007
Pautier P, Floquet A, Gladieff L, Bompas E, Ray-Coquard I, Piperno-Neumann S, Selle F, Guillemet C, Weber B, Largillier R, Bertucci F, Opinel P, Duffaud F, Reynaud-Bougnoux A, Delcambre C, Isambert N, Kerbrat P, Netter-Pinon G, Pinto N, Duvillard P, Haie-Meder C, Lhommé C, Rey A (2013) A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma group. Ann Oncol 24:1099–1104. https://doi.org/10.1093/annonc/mds545
Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S, Bernard L, Viale G, Pelicci PG, Di Fiore PP (2010) Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 140:62–73. https://doi.org/10.1016/j.cell.2009.12.007
Pfaendler KS, Tewari KS (2016) Changing paradigms in the systemic treatment of advanced cervical cancer. Am J Obstet Gynecol 214:22–30. https://doi.org/10.1016/j.ajog.2015.07.022
Piao LS, Hur W, Kim TK, Hong SW, Kim SW, Choi JE, Sung PS, Song MJ, Lee BC, Hwang D, Yoon SK (2012) CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma. Cancer Lett 315:129–137. https://doi.org/10.1016/j.canlet.2011.10.012
Pieterse Z, Amaya-Padilla MA, Singomat T, Binju M, Madjid BD, Yu Y, Kaur P (2019) Ovarian cancer stem cells and their role in drug resistance. Int J Biochem Cell Biol 106:117–126. https://doi.org/10.1016/j.biocel.2018.11.012
Powles T, Savage PM, Stebbing J, Short D, Young A, Bower M, Pappin C, Schmid P, Seckl MJ (2007) A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia. Br J Cancer 96:732–737. https://doi.org/10.1038/sj.bjc.6603608
Prager BC, Xie Q, Bao S, Rich JN (2019) Cancer stem cells: the architects of the tumor ecosystem. Cell Stem Cell 24:41–53. https://doi.org/10.1016/j.stem.2018.12.009
Qi W, Zhao C, Zhao L, Liu N, Li X, Yu W, Wei L (2014) Sorting and identification of side population cells in the human cervical cancer cell line HeLa. Cancer Cell Int 14:3. https://doi.org/10.1186/1475-2867-14-3
Qin Q, Sun Y, Fei M, Zhang J, Jia Y, Gu M, Xia R, Chen S, Deng A (2012) Expression of putative stem marker nestin and CD133 in advanced serous ovarian cancer. Neoplasma 59:310–315. https://doi.org/10.4149/neo_2012_040
Rappa G, Fodstad O, Lorico A (2008) The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells 26:3008–3017. https://doi.org/10.1634/stemcells.2008-0601
Reed NS, Mangioni C, Malmström H, Scarfone G, Poveda A, Pecorelli S, Tateo S, Franchi M, Jobsen JJ, Coens C, Teodorovic I, Vergote I, Vermorken JB, European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group (2008) Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 44:808–818. https://doi.org/10.1016/j.ejca.2008.01.019
Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414:105–111. https://doi.org/10.1038/35102167
Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445:111–115. https://doi.org/10.1038/nature05384
Roura E, Castellsagué X, Pawlita M, Travier N, Waterboer T, Margall N, Bosch FX, de Sanjosé S, Dillner J, Gram IT, Tjønneland A, Munk C, Pala V, Palli D, Khaw KT, Barnabas RV, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Fagherazzi G, Kaaks R, Lukanova A, Steffen A, Trichopoulou A, Trichopoulos D, Klinaki E, Tumino R, Sacerdote C, Panico S, Bueno-de-Mesquita HB, Peeters PH, Lund E, Weiderpass E, Redondo ML, Sánchez MJ, Tormo MJ, Barricarte A, Larrañaga N, Ekström J, Hortlund M, Lindquist D, Wareham N, Travis RC, Rinaldi S, Tommasino M, Franceschi S, Riboli E (2014) Smoking as a major risk factor for cervical cancer and pre-cancer: results from the EPIC cohort. Int J Cancer 135:453–466. https://doi.org/10.1002/ijc.28666
Roy L, Bobbs A, Sattler R, Kurkewich JL, Dausinas PB, Nallathamby P, Cowden Dahl KD (2018) CD133 promotes adhesion to the ovarian cancer metastatic niche. Cancer Growth Metastasis 11:1179064418767882. https://doi.org/10.1177/1179064418767882
Roy L, Cowden Dahl KD (2018) Can Stemness and Chemoresistance be therapeutically targeted via signaling pathways in ovarian cancer? Cancers (Basel) 10:241. https://doi.org/10.3390/cancers10080241
Ruhland MK, Loza AJ, Capietto AH, Luo X, Knolhoff BL, Flanagan KC, Belt BA, Alspach E, Leahy K, Luo J, Schaffer A, Edwards JR, Longmore G, Faccio R, DeNardo DG, Stewart SA (2016) Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis. Nat Commun 7:11762. https://doi.org/10.1038/ncomms11762
Rutella S, Bonanno G, Procoli A, Mariotti A, Corallo M, Prisco MG, Eramo A, Napoletano C, Gallo D, Perillo A, Nuti M, Pierelli L, Testa U, Scambia G, Ferrandina G (2009) Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. Clin Cancer Res 15:4299–4311. https://doi.org/10.1158/1078-0432.CCR-08-1883
Schmohl JU, Vallera DA (2016) CD133, selectively targeting the root of cancer. Toxins (Basel) 8:165. https://doi.org/10.3390/toxins8060165
Schulz A, Meyer F, Dubrovska A, Borgmann K (2019) Cancer stem cells and Radioresistance: DNA repair and beyond. Cancers (Basel) 11:862. https://doi.org/10.3390/cancers11060862
Schwarze SR, Shi Y, Fu VX, Watson PA, Jarrard DF (2001) Role of cyclin-dependent kinase inhibitors in the growth arrest at senescence in human prostate epithelial and uroepithelial cells. Oncogene 20:8184–8192. https://doi.org/10.1038/sj.onc.1205049
Seckl MJ, Sebire NJ, Fisher RA, Golfier F, Massuger L, Sessa C, ESMO Guidelines Working Group (2013) Gestational trophoblastic disease: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 10:39–50. https://doi.org/10.1093/annonc/mdt345
Shaheen S, Ahmed M, Lorenzi F, Nateri AS (2016) Spheroid-formation (Colonosphere) assay for in vitro assessment and expansion of stem cells in colon cancer. Stem Cell Rev Rep 12:492–499. https://doi.org/10.1007/s12015-016-9664-6
Sharrow AC, Perkins B, Collector MI, Yu W, Simons BW, Jones RJ (2016) Characterization of aldehyde dehydrogenase 1 high ovarian cancer cells: towards targeted stem cell therapy. Gynecol Oncol 142:341–348. https://doi.org/10.1016/j.ygyno.2016.03.022
Shepherd CJ, Rizzo S, Ledaki I, Davies M, Brewer D, Attard G, de Bono J, Hudson DL (2008) Expression profiling of CD133+ and CD133- epithelial cells from human prostate. Prostate 68:1007–1024. https://doi.org/10.1002/pros.20765
Shiraishi A, Tachi K, Essid N, Tsuboi I, Nagano M, Kato T, Yamashita T, Bando H, Hara H, Ohneda O (2017) Hypoxia promotes the phenotypic change of aldehyde dehydrogenase activity of breast cancer stem cells. Cancer Sci 108:362–372. https://doi.org/10.1111/cas.13147
Shmelkov SV, Clair RS, Lyden D, Rafii S (2005) AC133/CD133/Prominin-1. Int J Biochem Cell Biol 37:715–719. https://doi.org/10.1016/j.biocel.2004.08.010
Shmelkov SV, Jun L, St Clair R, McGarrigle D, Derderian CA, Usenko JK, Costa C, Zhang F, Guo X, Rafii S (2004) Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133. Blood 103:2055–2061. https://doi.org/10.1182/blood-2003-06-1881
Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821–5828
Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB (2004) Identification of human brain tumour initiating cells. Nature 432:396–401. https://doi.org/10.1038/nature03128
Skubitz AP, Taras EP, Boylan KL, Waldron NN, Oh S, Panoskaltsis-Mortari A, Vallera DA (2013) Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression. Gynecol Oncol 130:579–587. https://doi.org/10.1016/j.ygyno.2013.05.027
Slomovitz BM, Burke TW, Eifel PJ, Ramondetta LM, Silva EG, Jhingran A, Oh JC, Atkinson EN, Broaddus RR, Gershenson DM, Lu KH (2003) Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol 91:463–469. https://doi.org/10.1016/j.ygyno.2003.08.018
Soeda A, Park M, Lee D, Mintz A, Androutsellis-Theotokis A, McKay RD, Engh J, Iwama T, Kunisada T, Kassam AB, Pollack IF, Park DM (2009) Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 28:3949–3959. https://doi.org/10.1038/onc.2009.252
Song J, Chang I, Chen Z, Kang M, Wang CY (2010) Characterization of side populations in HNSCC: highly invasive, chemoresistant and abnormal Wnt signaling. PLoS One 5:e11456. https://doi.org/10.1371/journal.pone.0011456
Soslow RA, Tornos C, Park KJ, Malpica A, Matias-Guiu X, Oliva E, Parkash V, Carlson J, McCluggage WG, Gilks CB (2019) Endometrial carcinoma diagnosis: use of FIGO grading and genomic subcategories in clinical practice: recommendations of the International Society of Gynecological Pathologists. Int J Gynecol Pathol 38(Suppl 1):S64–S74. https://doi.org/10.1097/PGP.0000000000000518
Stemberger-Papić S, Vrdoljak-Mozetic D, Ostojić DV, Rubesa-Mihaljević R, Krigtofić I, Brncić-Fisher A, Kragević M, Eminović S (2015) Expression of CD133 and CD117 in 64 serous ovarian cancer cases. Coll Antropol 39:745–753
Stewart C, Ralyea C, Lockwood S (2019) Ovarian cancer: an integrated review. Semin Oncol Nurs 35:151–156. https://doi.org/10.1016/j.soncn.2019.02.001
Stewart JM, Shaw PA, Gedye C, Bernardini MQ, Neel BG, Ailles LE (2011) Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proc Natl Acad Sci U S A 108:6468–6473. https://doi.org/10.1073/pnas.1005529108
Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H (2006) Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 351:820–824. https://doi.org/10.1016/j.bbrc.2006.10.128
Tan LT, Tanderup K, Kirisits C, de Leeuw A, Nout R, Duke S, Seppenwoolde Y, Nesvacil N, Georg D, Kirchheiner K, Fokdal L, Sturdza A, Schmid M, Swamidas J, van Limbergen E, Haie-Meder C, Mahantshetty U, Jürgenliemk-Schulz I, Lindegaard JC, Pötter R (2019) Image-guided adaptive radiotherapy in cervical cancer. Semin Radiat Oncol 29:284–298. https://doi.org/10.1016/j.semradonc.2019.02.010
Tao Y, Li H, Huang R, Mo D, Zeng T, Fang M, Li M (2018) Clinicopathological and prognostic significance of cancer stem cell markers in ovarian cancer patients: evidence from 52 studies. Cell Physiol Biochem 46:1716–1726. https://doi.org/10.1159/000489586
Taylor F, Short D, Winter MC, Tidy J, Savage PM, Sarwar N, Hancock BW, Seckl MJ, Coleman RE (2015) A retrospective study to evaluate single agent methotrexate treatment in low risk gestational choriocarcinoma in the United Kingdom. Gynecol Oncol 136:258–263. https://doi.org/10.1016/j.ygyno.2014.12.024
Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, Monk BJ (2014) Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370:734–743. https://doi.org/10.1056/NEJMoa1309748
Tirino V, Desiderio V, d’Aquino R, De Francesco F, Pirozzi G, Graziano A, Galderisi U, Cavaliere C, De Rosa A, Papaccio G, Giordano A (2008) Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLoS One 3:e3469. https://doi.org/10.1371/journal.pone.0003469
Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, Fazioli F, Pirozzi G, Papaccio G (2011) Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo. FASEB J 25:2022–2030. https://doi.org/10.1096/fj.10-179036
Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, La Noce M, Laino L, De Francesco F, Papaccio G (2013) Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. FASEB J 27:13–24. https://doi.org/10.1096/fj.12-218222
Tsikouras P, Zervoudis S, Manav B, Tomara E, Iatrakis G, Romanidis C, Bothou A, Galazios G (2016) Cervical cancer: screening, diagnosis and staging. J BUON 21:320–325
Tyagi A, Vishnoi K, Mahata S, Verma G, Srivastava Y, Masaldan S, Roy BG, Bharti AC, Das BC (2016) Cervical cancer stem cells selectively overexpress HPV oncoprotein E6 that controls stemness and self-renewal through upregulation of HES1. Clin Cancer Res 22:4170–4184. https://doi.org/10.1158/1078-0432.CCR-15-2574
Ullah M, Azazzen D, Kaci R, Benabbou N, Pujade Lauraine E, Pocard M, Mirshahi M (2019a) High expression of HLA-G in ovarian Carcinomatosis: the role of interleukin-1β. Neoplasia 21:331–342. https://doi.org/10.1016/j.neo.2019.01.001
Ullah M, Pocard M, Mirshahi M (2019b) CD133 clinical trials: safety and efficacy. J Regen Med 8:2. https://doi.org/10.4172/2325-9620.1000151
van Neerven SM, Tieken M, Vermeulen L, Bijlsma MF (2015) Bidirectional interconversion of stem and non-stem cancer cell populations: a reassessment of theoretical models for tumor heterogeneity. Mol Cell Oncol 3:e1098791. https://doi.org/10.1080/23723556.2015.1098791
Vermeulen L, Todaro M, de Sousa MF, Sprick MR, Kemper K, Perez Alea M, Richel DJ, Stassi G, Medema JP (2008) Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci U S A 105:13427–13432. https://doi.org/10.1073/pnas.0805706105
Walcher L, Kistenmacher AK, Suo H, Kitte R, Dluczek S, Strauß A, Blaudszun AR, Yevsa T, Fricke S, Kossatz-Boehlert U (2020) Cancer stem cells-origins and biomarkers: perspectives for targeted personalized therapies. Front Immunol 11:1280. https://doi.org/10.3389/fimmu.2020.01280
Wang K, Zeng J, Luo L, Yang J, Chen J, Li B, Shen K (2013) Identification of a cancer stem cell-like side population in the HeLa human cervical carcinoma cell line. Oncol Lett 6:1673–1680. https://doi.org/10.3892/ol.2013.1607
Wei F, Zhang T, Deng SC, Wei JC, Yang P, Wang Q, Chen ZP, Li WL, Chen HC, Hu H, Cao J (2019) PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways. Cancer Lett 450:1–13. https://doi.org/10.1016/j.canlet.2019.02.022
Wei XD, Zhou L, Cheng L, Tian J, Jiang JJ, Maccallum J (2009) In vivo investigation of CD133 as a putative marker of cancer stem cells in Hep-2 cell line. Head Neck 31:94–101. https://doi.org/10.1002/hed.20935
Weigmann A, Corbeil D, Hellwig A, Huttner WB (1997) Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells. Proc Natl Acad Sci U S A 94:12425–12430. https://doi.org/10.1073/pnas.94.23.12425
Weiswald LB, Bellet D, Dangles-Marie V (2015) Spherical cancer models in tumor biology. Neoplasia 17:1–15. https://doi.org/10.1016/j.neo.2014.12.004
Weng D, Jin X, Qin S, Lan X, Chen C, Sun X, She X, Dong C, An R (2017) Radioimmunotherapy for CD133(+) colonic cancer stem cells inhibits tumor development in nude mice. Oncotarget 8:44004–44014. https://doi.org/10.18632/oncotarget.16868
WHO Classification of Tumors Editoral Board (2020) Female genital tumors (vol 4, 5th edn). WHO classification of tumors series. IARC: Lyon. Available online: https://publications.iarc.fr/592. Accessed 20 Dec 2020
Woelber L, Trillsch F, Kock L, Grimm D, Petersen C, Choschzick M, Jaenicke F, Mahner S (2013) Management of patients with vulvar cancer: a perspective review according to tumour stage. Ther Adv Med Oncol 5:183–192. https://doi.org/10.1177/1758834012471699
Wu C, Yu S, Tan Q, Guo P, Liu H (2018) Role of AhR in regulating cancer stem cell-like characteristics in choriocarcinoma. Cell Cycle 17:2309–2320. https://doi.org/10.1080/15384101.2018.1535219
Xi G, Hayes E, Lewis R, Ichi S, Mania-Farnell B, Shim K, Takao T, Allender E, Mayanil CS, Tomita T (2016) CD133 and DNA-PK regulate MDR1 via the PI3K- or Akt-NF-κB pathway in multidrug-resistant glioblastoma cells in vitro. Oncogene 35:5576. https://doi.org/10.1038/onc.2016.64
Xu R, Cai MY, Luo RZ, Tian X, Chen MK (2016) The expression status and prognostic value of cancer stem cell biomarker CD133 in cutaneous squamous cell carcinoma. JAMA Dermatol 152:305–311. https://doi.org/10.1001/jamadermatol.2015.3781
Xu T, Zeng Y, Shi L, Yang Q, Chen Y, Wu G, Li G, Xu S (2020) Targeting NEK2 impairs oncogenesis and radioresistance via inhibiting the Wnt1/β-catenin signaling pathway in cervical cancer. J Exp Clin Cancer Res 39:183. https://doi.org/10.1186/s13046-020-01659-y
Yap TA, Sandhu SK, Carden CP, de Bono JS (2011) Poly (ADP-ribose) polymerase (PARP) inhibitors: exploiting a synthetic lethal strategy in the clinic. CA Cancer J Clin 61:31–49. https://doi.org/10.3322/caac.20095
Yasin HK, Taylor AH, Ayakannu T (2021) A narrative review of the role of diet and lifestyle factors in the development and prevention of endometrial cancer. Cancers (Basel) 13:2149. https://doi.org/10.3390/cancers13092149
Yi Y, Fang Y, Wu K, Liu Y, Zhang W (2020) Comprehensive gene and pathway analysis of cervical cancer progression. Oncol Lett 19:3316–3332. https://doi.org/10.3892/ol.2020.11439
Yin S, Li J, Hu C, Chen X, Yao M, Yan M, Jiang G, Ge C, Xie H, Wan D, Yang S, Zheng S, Gu J (2007) CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 120:1444–1450. https://doi.org/10.1002/ijc.22476
Zeng S, Shen WH, Liu L (2018) Senescence and cancer. Cancer Transl Med 4:70–74. https://doi.org/10.4103/ctm.ctm_22_18
Zhang J, Guo X, Chang DY, Rosen DG, Mercado-Uribe I, Liu J (2012) CD133 expression associated with poor prognosis in ovarian cancer. Mod Pathol 25:456–464. https://doi.org/10.1038/modpathol.2011.170
Zhang Q, Shi S, Yen Y, Brown J, Ta JQ, Le AD (2010) A subpopulation of CD133(+) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy. Cancer Lett 289:151–160. https://doi.org/10.1016/j.canlet.2009.08.010
Zheng R, Heller DS (2019) Borderline Brenner tumor: a review of the literature. Arch Pathol Lab Med 143:1278–1280. https://doi.org/10.5858/arpa.2018-0285-RS
Zhong X, Li Y, Peng F, Huang B, Lin J, Zhang W, Zheng J, Jiang R, Song G, Ge J (2007) Identification of tumorigenic retinal stem-like cells in human solid retinoblastomas. Int J Cancer 121:2125–2131. https://doi.org/10.1002/ijc.22880
Zhou HM, Zhang JG, Zhang X, Li Q (2021) Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents. Signal Transduct Target Ther 6:62. https://doi.org/10.1038/s41392-020-00430-1
Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Deng J, Margolick JB, Liotta LA, Petricoin E 3rd, Zhang Y (2007) Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A 104:16158–16163. https://doi.org/10.1073/pnas.0702596104
Zhou Q, Chen A, Song H, Tao J, Yang H, Zuo M (2015) Prognostic value of cancer stem cell marker CD133 in ovarian cancer: a meta-analysis. Int J Clin Exp Med 8:3080–3088
Acknowledgments and Funding Information
This chapter is based upon work from COST Action CA18117 – European network for Gynaecological Rare Cancer research: From Concept to Cure (GYNOCARE), supported by COST (European Cooperation in Science and Technology). COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. Our actions help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career, and innovation. www.cost.eu
Conflicts of Interest
The authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Di Fiore, R., Suleiman, S., Calleja-Agius, J. (2023). CD133 as Biomarker and Therapeutic Target in Gynecologic Malignancies. In: Interdisciplinary Cancer Research. Springer, Cham. https://doi.org/10.1007/16833_2023_139
Download citation
DOI: https://doi.org/10.1007/16833_2023_139
Published:
Publisher Name: Springer, Cham